These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23389493)

  • 1. Lean systems approaches to health technology assessment: a patient-focused alternative to cost-effectiveness analysis.
    Bridges JF
    Pharmacoeconomics; 2006 Dec; 24 Suppl 2():101-9. PubMed ID: 23389493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strengthening cost-effectiveness analysis in Thailand through the establishment of the health intervention and technology assessment program.
    Tantivess S; Teerawattananon Y; Mills A
    Pharmacoeconomics; 2009; 27(11):931-45. PubMed ID: 19888793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].
    Garrison LP; Neumann PJ; Willke RJ; Basu A; Danzon PM; Doshi JA; Drummond MF; Lakdawalla DN; Pauly MV; Phelps CE; Ramsey SD; Towse A; Weinstein MC
    Value Health; 2018 Feb; 21(2):161-165. PubMed ID: 29477394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Health technology assessment (HTA). Developments in healthcare and potential for radiology].
    Gizewski ER; Forsting M; Krombach GA; Schöffski O
    Radiologe; 2014 Jun; 54(6):589-98. PubMed ID: 24844855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation approaches for new technology.
    Papatheofanis FJ
    IEEE Eng Med Biol Mag; 2003; 22(3):16-7. PubMed ID: 12845811
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug Policy in the Russian Federation.
    Holownia-Voloskova M; Vorobiev PA; Grinin M; Davydovskaya MV; Ermolaeva TN; Kokushkin KA
    Value Health Reg Issues; 2018 Sep; 16():106-111. PubMed ID: 30327255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Value of Medicines: A Crucial but Vague Concept.
    Antoñanzas F; Terkola R; Postma M
    Pharmacoeconomics; 2016 Dec; 34(12):1227-1239. PubMed ID: 27444306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value-based approaches to healthcare systems and pharmacoeconomics requirements in Asia: South Korea, Taiwan, Thailand and Japan.
    Kamae I
    Pharmacoeconomics; 2010; 28(10):831-8. PubMed ID: 20831290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there an alternative to quality-adjusted life years for supporting healthcare decision making?
    Beresniak A; Dupont D
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):351-7. PubMed ID: 27139424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the value of implementing reimbursement decisions: What can payers and manufacturers learn from economics?
    Dixon S
    Healthc Manage Forum; 2019 Nov; 32(6):303-306. PubMed ID: 31248283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linking the Regulatory and Reimbursement Processes for Medical Devices: The Need for Integrated Assessments.
    Ciani O; Wilcher B; van Giessen A; Taylor RS
    Health Econ; 2017 Feb; 26 Suppl 1():13-29. PubMed ID: 28139087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of costs for health economic evaluation.
    Riewpaiboon A
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S17-26. PubMed ID: 24964695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health technology assessment in Saudi Arabia.
    Al-Aqeel S
    Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):393-402. PubMed ID: 29733227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How is the Societal Perspective Defined in Health Technology Assessment? Guidelines from Around the Globe.
    Avşar TS; Yang X; Lorgelly P
    Pharmacoeconomics; 2023 Feb; 41(2):123-138. PubMed ID: 36471131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations.
    Shiroiwa T; Fukuda T; Ikeda S; Takura T
    Health Policy; 2017 Aug; 121(8):836-841. PubMed ID: 28687183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prioritizing investments in health technology assessment. Can we assess potential value for money?
    Davies L; Drummond M; Papanikolaou P
    Int J Technol Assess Health Care; 2000; 16(1):73-91. PubMed ID: 10815355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Health technology assessment: II. Cost effectiveness analysis].
    Secoli SR; Nita ME; Ono-Nita SK; Nobre M
    Arq Gastroenterol; 2010; 47(4):329-33. PubMed ID: 21225140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.
    Eckermann S; Willan AR
    Pharmacoeconomics; 2011 Jul; 29(7):563-77. PubMed ID: 21671686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness thresholds: methods for setting and examples from around the world.
    Santos AS; Guerra-Junior AA; Godman B; Morton A; Ruas CM
    Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):277-288. PubMed ID: 29468951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.